Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activate Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia

Karina Calvopiña, Punyawee Dulyayangkul, Matthew B Avison*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)

4 Downloads (Pure)

Abstract

Aminoglycoside resistance in Stenotrophomonas maltophilia is multifactorial, but the most significant mechanism is overproduction of the SmeYZ efflux system. By studying laboratory selected mutants and clinical isolates, we show here that damage to the 50S Ribosomal protein L1 (RplA) activates SmeYZ production. We also show that gentamicin and minocycline, which target the ribosome, induce expression of smeYZ These findings explain the role of SmeYZ in both intrinsic and mutationally acquired aminoglycoside resistance.

Original languageEnglish
Article numbere01524-19
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume64
Issue number2
DOIs
Publication statusPublished - 27 Jan 2020

Fingerprint Dive into the research topics of 'Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activate Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia'. Together they form a unique fingerprint.

  • Cite this